Loading
RT
Regulus Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Klassen Preston, was filed 04 Jun 2025.
Regulus Therapeutics Inc.: what insiders have been doing
This page follows insider dealings at Regulus Therapeutics Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Regulus Therapeutics Inc. has had no insider filing for more than a year; the last one goes back to 27 June 2025.
Since 2020, the database holds 17 purchases and 13 sales by insiders of the company.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
64
Thresholds
n/a
Buy Volume
€23M
17 ops. · all time
Sell Volume
€313,490
13 ops. · all time
Who traded when
BuySaleJoseph P. Hagan1 buy1 sale
Preston Klassen1 buy1 sale
Christopher Ray Aker1 sale
Crispina Calsada1 sale
David Baltimore1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
Net income-US$39.9M
Last declaration on 27 June 2025
Declarations64 total
976,253 sharesCommon StockSEC:0000950170-25-091032:0
75,565 sharesCommon StockSEC:0000950170-25-090992:0
6,979 sharesCommon StockSEC:0000950170-25-091026:0
62,500 sharesCommon StockSEC:0000950170-25-091006:0
5,208 sharesCommon StockSEC:0000950170-25-091003:0
44,264 sharesCommon StockSEC:0000950170-25-091036:0
67,233 sharesCommon StockSEC:0000950170-25-091035:0
115,555 sharesCommon StockSEC:0000950170-25-091020:0
60,796 sharesCommon StockSEC:0000950170-25-091019:0
571,558 sharesCommon StockSEC:0000950170-25-091015:0
27,377 sharesCommon StockSEC:0000950170-25-091008:0
140,228 sharesCommon StockSEC:0000950170-25-090986:0
1,396 shares@ US$9.9064.1% of flowCommon StockSEC:0000950170-25-087947:0
12,000 shares@ US$7.987748.8% of flowCommon StockSEC:0000950170-25-081715:0
Canonical exit: 1 Sept 2025 (T+90)
62,500 shares0Common StockSEC:0000950170-25-061114:0
62,500 shares0Common StockSEC:0000950170-25-061118:0
62,500 shares0Common StockSEC:0000950170-25-061115:0
62,500 shares0Common StockSEC:0000950170-25-061117:0
62,500 shares0Common StockSEC:0000950170-25-061111:0
62,500 shares0Common StockSEC:0000950170-25-061298:0
62,500 shares0Common StockSEC:0000950170-25-061119:0
62,500 shares0Common StockSEC:0000950170-25-061113:0
62,500 shares0Common StockSEC:0000950170-25-061118:1
50,000 shares@ US$1.085210.0% of flowCommon StockSEC:0000950170-25-011853:0
Canonical exit: 30 Apr 2025 (T+90)
19,610 shares@ US$1.06100.0% of flowCommon StockSEC:0000950170-25-011850:0
Canonical exit: 30 Apr 2025 (T+90)
25 of 64 declarations
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc. (ticker: RGLS) is a U.S.-listed biopharmaceutical company traded on the Nasdaq market in the United States and focused on microRNA-based medicines. The company develops oligonucleotide therapeutics designed to inhibit dysregulated microRNA targets, with an initial emphasis on genetically defined orphan diseases, especially inherited kidney disorders. Its principal executive offices are in San Diego, California. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai))
Regulus was originally established in 2007, following work tied to Alnylam and Ionis around microRNA-targeting therapeutics, and it was converted into a Delaware corporation in January 2009. That history matters because it explains the company’s long-standing positioning as a science-driven, platform-oriented biotech rather than a broad commercial pharmaceutical business. Over time, Regulus has built expertise in RNA drug discovery and development, with a focus on mechanisms that regulate gene expression at the microRNA level. ([sec.gov](https://www.sec.gov/Archives/edgar/data/874015/000087401518000047/form10k.htm?utm_source=openai))
Read moreShow less
Operationally, Regulus is best described as a clinical-stage specialty biotech with a narrow but potentially differentiated pipeline. Its lead focus is ADPKD, or autosomal dominant polycystic kidney disease, where it is pursuing an anti-miR-17 strategy intended to address the underlying biology of the disease. The company’s lead asset, farabursen (RGLS8429), is the flagship program and the central driver of its value proposition. Regulus also highlights the strength of its intellectual-property position, including exclusive licensed IP from Alnylam and Ionis plus internal discoveries since inception. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai))
In competitive terms, Regulus occupies a niche within RNA therapeutics and genetic kidney disease. It is not a large diversified biotech; instead, it competes on scientific novelty, translational relevance, and clinical data quality. That makes the company highly dependent on clinical execution, regulatory outcomes, and capital discipline, but also gives it the potential for significant re-rating if its lead program demonstrates compelling efficacy and safety. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai))
A major recent development was the April 30, 2025 announcement that Regulus entered into a merger agreement with Novartis AG. Under the deal, Novartis agreed to acquire Regulus for $7.00 per share in cash at closing, with an additional contingent value right tied to a regulatory milestone for farabursen. For investors, this is the key headline: RGLS is no longer just a standalone microRNA story, but also a live M&A situation with a strategic buyer validating the platform and lead asset. ([nasdaq.com](https://www.nasdaq.com/press-release/regulus-therapeutics-enters-agreement-be-acquired-novartis-ag-2025-04-30?utm_source=openai))
